Exploring links between vitamin D deficiency and COVID-19.
Mradul MohanJerin Jose CherianAmit SharmaPublished in: PLoS pathogens (2020)
Coronavirus Disease 2019 (COVID-19) pandemic remains a major public health threat in most countries. The causative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus can lead to acute respiratory distress syndrome and result in mortality in COVID-19 patients. Vitamin D is an immunomodulator hormone with established effectiveness against various upper respiratory infections. Vitamin D can stall hyper-inflammatory responses and expedite healing process of the affected areas, primarily in the lung tissue. Thus, there are ecological and mechanistic reasons to promote exploration of vitamin D action in COVID-19 patients. As no curative drugs are available currently for COVID-19, we feel that the potential of vitamin D to alter the course of disease severity needs to be investigated. Clinical studies may be undertaken to address the value of vitamin D supplementation in deficient, high-risk COVID-19 patients.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- acute respiratory distress syndrome
- public health
- extracorporeal membrane oxygenation
- mechanical ventilation
- systematic review
- cardiovascular disease
- human health
- type diabetes
- risk factors
- intensive care unit
- rectal cancer
- high resolution
- cardiovascular events
- coronary artery disease
- respiratory tract
- atomic force microscopy
- prognostic factors
- drug induced